{"url_path":"/sec/mist/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-059752-index.html","accession_number":"0001104659-26-059752","cik":"0001408443","ticker":"MIST","issuer_name":"Milestone Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-059752-index.html","primary_entity_key":"0001408443","primary_entity_name":"Milestone Pharmaceuticals Inc."},"word_count":515,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n​\n\n​\n\n​\n\n**Exhibit**\n**Number**\n\n  ​ ​ ​\n\n**Description**\n\n​\n\n​\n\n​\n\n3.1\n\n​\n\n[Amended Articles of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on May 15, 2019).](http://www.sec.gov/Archives/edgar/data/1408443/000110465919029792/a18-41190_11ex3d1.htm)\n\n3.2\n\n​\n\n[Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on May 15, 2019).](http://www.sec.gov/Archives/edgar/data/1408443/000110465919029792/a18-41190_11ex3d2.htm)\n\n10.1+\n\n​\n\n[Non-Employee Director Compensation Policy, as amended.](mist-20260331xex10d1.htm)\n\n10.2+**\n\n​\n\n[Employment Agreement, dated January 19, 2026, between David Sandoval and Milestone Pharmaceuticals Inc.](mist-20260331xex10d2.htm)\n\n10.3\n\n​\n\n[Controlled Equity OfferingSM dated May 13, 2026, by and between Milestone Pharmaceuticals Inc. and Cantor Fitzgerald & Co.](mist-20260331xex10d3.htm)\n\n31.1\n\n​\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](mist-20260331xex31d1.htm)\n\n42\n\n[Table of Contents](#TOC)\n\n​\n\n31.2\n\n​\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](mist-20260331xex31d2.htm)\n\n32.1*\n\n​\n\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](mist-20260331xex32d1.htm)\n\n101.INS\n\n​\n\nInline XBRL Instance Document\n\n101.SCH\n\n​\n\nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL\n\n​\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF\n\n​\n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB\n\n​\n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE\n\n​\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104\n\n​\n\nThe cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL.\n\n​\n\n*        Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the “Exchange Act (whether made before or after the date of the Form 10-Q)”, irrespective of any general incorporation language contained in such filing.\n\n​\n\n+\n\nIndicates a management contract or compensatory plan.\n\n​\n\n**\n\nCertain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.\n\n​\n\n​\n\n43\n\n[Table of Contents](#TOC)\n\n​\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\nMILESTONE PHARMACEUTICALS INC.\n\n​\n\n​\n\nDate: May 13, 2026\n\nBy:\n\n/s/ Joseph Oliveto\n\n​\n\n​\n\n**Joseph Oliveto**\n\n​\n\n​\n\n**President and Chief Executive Officer**\n**(Principal Executive Officer)**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nDate: May 13, 2026\n\nBy:\n\n/s/ Amit Hasija\n\n​\n\n​\n\n**Amit Hasija**\n\n​\n\n​\n\n**Chief Financial Officer********(Principal Financial Officer and Principal Accounting Officer)**\n\n​\n\n​\n\n44"}